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Background: The 6-min walk distance (6MWD) and incremental shuttle walk distance (ISWD)
are clinically meaningful measures of exercise capacity in people with non-cystic fibrosis
(CF) bronchiectasis, but the change in walking distance which constitutes clinical benefit is un-
defined. This study aimed to determine the minimal important difference for the 6MWD and
ISWD in non-CF bronchiectasis.
Methods: Thirty-seven participants with mean FEV1 70% predicted completed both field
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1304 A.L. Lee et al.was calculated using a distribution-based and anchor-based method, with the global rating of
change scale used.
Results: The mean change in 6MWD in participants who reported themselves to be unchanged
was 10 m, compared to 36 m (small change) and 45 m (substantial change) (pZ 0.01). For the
ISWD, the mean change in participants who reported themselves to be unchanged was 33 m,
compared to 54 m (small change) and 73 m (substantial change) (p Z 0.04). The anchor-
based method defined the minimal important difference for 6MWD as 24.5 m (AUC 0.76, 95%
CI 0.61e0.91) and for ISWD as 35 m (AUC 0.88, 95% CI 0.73e0.99), based on participant’s global
rating of change. The distribution-based method indicated a value of 22.3 m for the 6MWD and
37 m for the ISWD. There was excellent agreement between the two methods for the 6MWD
(kappa Z 0.91) and the ISWD (kappa Z 0.92).
Conclusions: Small changes in 6MWD and ISWD may represent clinically important benefits in
people with non-CF bronchiectasis. These data are likely to assist in the interpretation of
change in exercise capacity following intervention.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
For patients with non-cystic fibrosis (CF) bronchiectasis,
chronic sputum production, fatigue, dyspnoea and reduced
exercise tolerance are commonly reported symptoms
[1e3]. Current guidelines for management recommend a
variety of strategies, including both medical and physio-
therapy treatment approaches [4]. Field walking tests
including the 6-min walk test (6MWT) and incremental
shuttle walk test (ISWT) are often applied as outcome
measures to determine effects of interventions on exercise
capacity and in bronchiectasis they have been used to
evaluate treatment effects for antibiotic therapy [5],
airway clearance techniques [6], inspiratory muscle
training [7] and pulmonary rehabilitation [8e11].
Although a number of different therapies have signifi-
cantly improved physical endurance in bronchiectasis
[5,8,9,11], interpreting the clinical significance of these
changes remains a challenge. The minimal important dif-
ference (MID) is defined as the smallest change in an outcome
measure that is recognised to be beneficial by the patient
and that would lead a clinician to consider a change in
therapy [12,13]. Several methods can be used to determine
this threshold of change and a combined approach is gener-
ally recommended [14]. One method utilises an external
criterion (or anchor state) to estimate theMID [12,15], which
involves comparing the magnitude of change in an outcome
to another clinically relevant measure [15]. A common
example of an external criterion is an ordinal rating of
change perceived by the patient or clinician as improvement
or decline [12,16]. Distribution-based methods compare the
change in score to ameasure of variability, whichmay be the
standard error ofmeasurement (SEM) or effect size (ES). This
method analyses the statistical properties of the measures
based on the study sample data for the outcome variable
[17]. Because MIDs may vary across individuals, reporting a
range of MIDs is appropriate [13]. This combined approach
has been utilised to estimate the MID in other chronic res-
piratory disease populations [18e20].
The need for more clinical markers in bronchiectasis has
been recently identified as a necessity to determine theeffectiveness of treatment [21]. Both the 6MWT and ISWT
are simple field walking tests, with the 6MWT measuring
functional exercise capacity [22], and the ISWT being an
incremental test, reflecting peak exercise capacity [23].
The performance of both may be influenced by the severity
of lung disease [24,25]. To date, there is no accepted
threshold for clinically relevant change in these two field
walking tests in bronchiectasis. The aims of this study were
to (1) prospectively determine MID for the 6MWT and the
ISWT in patients with non-CF bronchiectasis and (2) to
determine whether there is a difference in the MID calcu-
lated using both anchor and distribution-based methods.
Methods
Participants
Patients with non-CF bronchiectasis based on high resolution
computed tomography (HRCT) were recruited from three
tertiary hospitals. All were participants in a randomised
controlled trial evaluating the efficacy of exercise training in
this patient population [26]. Patients were eligible to partic-
ipate if they reported dyspnoea on exertion (ModifiedMedical
Research Council Dyspnoea grade of 1 [27] at baseline
assessment and had no neurological and musculoskeletal
comorbidities which compromised exercise training. Exclu-
sion criteria were a diagnosis of chronic obstructive pulmo-
nary disease (COPD) (basedon thecriterion of FEV1/FVC< 70,
smoking history of greater than 10 pack years and evidence of
emphysema on HRCT) [28]), asthma, interstitial lung disease
or CF and other conditions (orthopaedic, neurological,
vascular) which limited the ability to safely or effectively
undertake exercise. The study was approved by human
research ethics committees at all institutions, with written
informed consent obtained from all participants.
Study design
The 6-min walk distance (6MWD) and the incremental
shuttle walk distance (ISWD) were measured on consecutive
Table 1 Baseline participant characteristics (n Z 37).
Mean (SD) Range
Age (years) 63 (13) 58e80
BMI (kg m2) 24.7 (5.9) 21.2e33.2
MMRC 1.3 (0.5) 1e3
FEV1 % predicted 76.9 (18.3) 60.8e92.1
FVC % predicted 83.8 (17.6) 70.8e97.0
6MWD (m) 551 (90) 373e759
6MWD (% predicted)a 85 (12) 77e96
ISWD (m) 464 (150) 200e780
ISWD (% predicted)b 76 (24) 59e94
BMI e Body mass index; MMRC e Modified Medical Research
Council Dyspnoea grade; FEV1 e Forced expiratory volume in
1 s; FVC e Forced vital capacity; 6MWD e 6-min walk distance;
ISWD e Incremental shuttle walk distance.
a Predicted values for 6MWD based on reference [34].
b Predicted values for ISWD based on reference [35].
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order, using a standard protocol for both tests [22,23]. All
participants completed two of each test on each occasion
with the best 6MWD and ISWD recorded. Participants un-
dertook an eight-week exercise training program, which
consisted of a twice weekly supervised program of 30 min of
lower limb endurance exercise and 20 min of circuit weight
training for the upper and lower limbs [29] as previously
described [26]. At the conclusion of the training period, but
prior to repeating the field walking tests, the global rating
of change (GROC) scale was administered by an indepen-
dent data collector, to determine the amount of change in
walking ability perceived by the participants. Participants
were asked if there had been a change in their walking
ability since the beginning of the exercise program with the
options of answering ‘worse’, ‘better’ or ‘no change’. The
amount of change was scored based on a Likert scale as:
0 e no change, 1 e almost the same, hardly any change, 2 e
a little worse/better, 3 e somewhat worse/better, 4 e
moderately worse/better, 5 e a good deal worse/better, 6
e a great deal worse/better and 7 e a very great deal
worse/better [12]. Scores of 0e1 were classed as no
change, scores of 2e3 were small changes and scores of
4e7 were substantial changes, with these classifications
previously used to determine change in individuals with
respiratory disease [19]. To identify the agreement be-
tween the participant and clinician, the clinician respon-
sible for training at each site also rated the change in the
participant’s walking ability using the same criteria at the
same time point. Clinicians and participants were blinded
to each other’s ratings and the 6MWD and ISWD at the
conclusion of the intervention.
The change in walking distance for the 6MWD and ISWD
were expressed as an absolute distance from the baseline
result. The mean changes in 6MWD and ISWD corresponding
to no change, small improvement and substantial
improvement in walking ability were compared using
analysis of variance. Because walking distance may be
influenced by demographic factors, changes in walking
distance for those who reported clinical change were
compared according to age (<65 years vs >65 years),
gender and severity of lung disease (FEV1 < 50% predicted;
FVC <50% predicted) [30], as these factors affect 6MWD
and prognosis in bronchiectasis. For the anchor-based
approach, participants were considered ‘changed’ if they
had a score of 2 or more on the GROC scale. A receiver
operating characteristic (ROC) curve was used to determine
the optimal threshold for detection of change, with the
data point closest to the upper left corner of the curve
representing the MID [31]. This analysis was repeated with
walking distance classified as ‘changed’ or ‘unchanged’
according to the clinicians’ GROC scores, with the same
cut-off score of 2 used to distinguish between participants.
The area under curve (AUC) of the ROC determined the
accuracy of the outcome measure.
In order to derive the MID with the distribution-based
method, both the ES and SEM were calculated. The ES is a
standardised measure of change which was obtained by
dividing the difference in scores from baseline to post
treatment by the SD of the baseline scores. A moderate ES is
considereda clinically importanteffect andwas calculatedas
0.5  SD of the change scores [32]. The formula for derivingthe SEMwasdefinedas ơ1$O(1 ICC), where ơ1 is the baseline
SD and the intraclass correlation coefficient (ICC) is the test-
retest reliability, calculated using the two 6MWDs and the
ISWDs conducted for each participant at the conclusion of the
program[33].OneSEMclosely approximates theMID [33]. The
agreement between the proportion of participants who were
classified as changed under the ROC and SEM methods were
analysed using Cohen’s correlation coefficient.
Results
A total of 42 participants were recruited, with demographic
characteristics outlined on Table 1. Four participants did not
complete the exercise program. Five participants failed to
undertake their 6MWT and ISWT at the end of intervention,
two were unwell, two declined to attend and one withdrew
from the study. Follow up data were therefore obtained for
37 participants. There was a range of 6MWDs (373e759 m)
and ISWDs (200e780 m). Most participants (76%) had a rating
of mild functional impairment secondary to dyspnoea
(Modified Medical Research Council Dyspnoea grade of 1)
[27]. The majority (60%) of participants had moderate dis-
ease severity based on spirometry, with 38% having severe
disease and one had very severe disease [28]. Nineteen
participants had bronchiectasis due to a preceding pulmo-
nary infection, 11were classified as idiopathic, fivewere due
to an immunodeficiency disorder and two were due to pri-
mary ciliary dyskinesia. Common comorbidities were sys-
temic hypertension (n Z 10), hypercholesterolaemia
(n Z 2), Type 11 diabetes mellitus (n Z 2), fibromyalgia
(n Z 2) and osteoporosis (n Z 3). Common medications
included: Colistin (n Z 2), short-acting bronchodilators
(n Z 12), inhaled corticosteroid (n Z 3), long term antibi-
otics (nZ 3) and hypertonic saline (nZ 5).
Following exercise training there was a mean improve-
ment in 6MWD of 41 m (95% CI 19e63 m) and in the ISWD of
62 m (95% CI 24e101 m). The participant global rating of
change scores indicated no change in walking ability in six
participants, a small improvement in six participants and
substantial improvement in 25 participants. The mean
change in 6MWD in those who classified themselves as
Figure 1 Relationship between change in A) 6MWD and B)
ISWD and global rating of change in walking ability following
exercise training. Data are means and standard deviations.
*p < 0.05 comparing none vs substantial. 6MWD e 6-min walk
distance; ISWD e incremental shuttle walk distance.
1306 A.L. Lee et al.unchanged was 10 m, compared to 36 m in those reporting
small changes and 45 m in those reporting substantial
change (p Z 0.001). For the ISWD, the mean change in
those classing themselves as unchanged was 33 m,
compared to 54 m in those reporting small changes andFigure 2 Change in A) 6MWD and B) ISWD in participants who rep
age; Data are mean and 95% CI.73 m in those reporting substantial changes (p Z 0.04)
(Fig. 1). There were no differences in the magnitude of
change in either the 6MWD or the ISWD that participants
classed as clinically important related to gender, severity of
lung disease or age (Fig. 2).
The ROC curve based on participant ratings indicated a
threshold value for clinically significant change in the 6MWD
of 24.5 m, with a corresponding sensitivity of 72% and
specificity of 75% (AUC 0.76 [95% CI 0.61 to 0.9]). The
positive predictive value (PPV) for this change was 78% with
a negative predictive value (NPV) of 71%. For the ISWD, the
ROC curve indicated a threshold for clinically significant
change of 35 m, which corresponded to a sensitivity of 88%
and specificity of 83% (AUC 0.88 [95% CI 0.73 to 0.99])
(see Fig. 3). The PPV for this threshold was 68%, with a NPV
of 70%. There was agreement between participants and
clinicians regarding clinical change, with consensus in 30
(81%) participants. The ROC curves based on clinician rat-
ings indicated a threshold for the 6MWD of 22.5 m, with a
sensitivity of 75% and specificity of 61% (AUC of 0.81 [0.67
to 0.95]). For the ISWD, the clinician threshold was 35 m,
with specificity of 69% and sensitivity of 83% (AUC of 0.80
[0.64 to 0.95]).
According to the distribution-based methods for the
6MWD, the SEM was 22.5 m, using the baseline SD for 6MWD
of 93.3 m and an ICC of 0.98. Based on the ES calculation,
the MID was 20 m. For the ISWD, the MID according to the
SEM was 37 m, using the baseline SD of 150 m and an ICC of
0.97 and based on ES, the MID was 32 m. In a comparison of
the anchor (using participant ratings) versus distribution-
based method, the agreement for the proportion of par-
ticipants who were classified as changed was strong for the
6MWD (kappa 0.91 (95% CI 0.83e0.97) and the ISWD (kappa
0.92 (95% CI 0.79e0.99). During the eight-week program, 24
(65%) participants achieved an improvement of more than
24.5 m in the 6MWD and 20 (54%) achieved an improvement
of more than 35 m in the ISWD.Discussion
The 6MWT and ISWT are emerging as commonly used mea-
sures of exercise capacity in patients with bronchiectasis.orted clinical change. according to gender, disease severity and
Figure 3 Receiver operating characteristic curves for change
in A) 6MWD and B) ISWD.
Important difference in walking tests in bronchiectasis 1307To our knowledge, this is the first report describing the MID
for both the 6MWD and ISWD in individuals with non-CF
bronchiectasis. In this study of people with predominantly
moderate bronchiectasis based on spirometry measures
[28], the estimated MID of the 6MWD was 25 m and for the
ISWD was 35 m. There was little difference between the
anchor-based and distribution-based methods. The
threshold for change did not differ based on participant
versus clinician ratings.
The MID values for the 6MWD reported here are com-
parable to those in other respiratory populations. According
to estimates which have applied similar anchor and
distribution-based analyses, the MID in COPD has ranged
between 25 and 35 m [19,20,36,37] and in interstitial lung
disease, the MID is reported to be between 24 and 45 m
[18,40,41] (Table 2). To estimate the anchor-based MID, we
applied an external criterion which was specific toTable 2 Minimal important difference in 6MWD in other respira
References
Holland 2010 [19], Puhan 2008, 2011 [20,36], Polkey 2013 [37]
Gilbert 2009 [38], Mathai 2012 [39]
Holland 2009 [18]
Holland 2009 [18], du Bois 2001 [40], Swigris 2010 [41]
COPD e chronic obstructive pulmonary disease; 6MWD e 6-min walkfunctional exercise capacity, which has a strong correlation
to change in exercise capacity [12], and a similar approach
has been applied in some aforementioned studies [18,19]. It
suggests that despite the baseline mean of the 6MWD in this
group of patients being high (>500 m), a difference in
6MWD following this form of intervention was able to be
detected by patients. A further advantage of the ROC curve
is the ability to calculate PPV and NPV. Based on these
results, with a 24.5 m threshold, we can conclude that in
this representative population, 78% of participants who
improved in the 6MWD by this distance or more perceived a
meaningful clinical change in walking ability. Conversely, in
participants who improved by less than 24.5 m, 71% did not
perceive a change. For the ISWD, 68% of participants who
improved in the ISWD by 35 m or more perceived a mean-
ingful change in walking ability, while in those with a
change less than 35 m, 70% did not perceive a meaningful
change. In addition, the high specificity of this MID at 72%
based on the anchor-based analysis indicates that if a dif-
ference in ISWD does not reach 35 m, it is unlikely that a
clinically significant change has occurred.
Only one previous study has described the MID for the
ISWD [42], where the MID of 47.5 m in patients with COPD
was somewhat greater than that identified in our study of
bronchiectasis. A possible reason is a different approach in
evaluating the presence of a change in exercise capacity.
While a patient-rating of subjective improvement was uti-
lised, the mean values for ‘small change’ and ‘substantial
change’ were reported, without a threshold value for
detecting such a change, and a distribution-based method
was not reported. Despite this, the lower bound of the CI
reported by Singh et al. (38.6e56.5 m) [42] is close to the
MID estimated in the current study. Furthermore, the high
specificity described in the current study at 83% reinforces
the likelihood that in individuals with bronchiectasis, a
clinically significant improvement is unlikely to be evident
without a change of 35 m in distance.
The estimation of the MID for both walking tests was
similar when based on the participant or clinician ratings of
change. This is in contrast to previous reports of disagree-
ment between patients’ and clinicians’ ratings of change
[43], with the suggestion that clinicians overestimate the
extent of functional change [44]. The opportunity to
observe participants over the longer term within the
rehabilitation setting may account for the high level of
agreement (81%) in this study.
Identifying thresholds for clinically important change in
the 6MWD and ISWD assists in interpreting the effects of
both medical therapeutic approaches and physiotherapy on
functional exercise capacity. Although both tests are a
reliable measure of exercise in non-CF bronchiectasistory conditions.
Respiratory condition 6MWD MID
COPD 25 to 35 m
Pulmonary hypertension 31 to 39 m
Diffuse parenchyma lung disease 31 to 33 m
Idiopathic pulmonary fibrosis 22 to 45 m
distance; MID e minimal important difference.
1308 A.L. Lee et al.[45,46], knowledge of the MIDs assists in interpreting the
clinical significance of observed effects in clinical trials.
With the continued growth of interventional studies in non-
CF bronchiectasis [6e9,26], this is valuable within clinical
practice and future research studies.
Our study has limitations. The majority of participants
had moderate bronchiectasis, with mild levels of functional
impairment. Therefore, the generalisability of these
thresholds for MID for both field walking tests to all pa-
tients across the disease spectrum, including the severity
of bronchiectasis based on HRCT scoring and degree of
functional impairment is uncertain. However, participants
had a wide range of functional walking capacity (Table 1).
This variability gave rise to baseline standard deviations
similar to those reported in previous MID studies of other
populations [36], suggesting that distribution-based esti-
mates were not likely to be adversely affected by the
relatively small size of our sample. There were a small
number of participants who were not able to complete
their 6MWD or ISWD following intervention; the absence of
this information in analysis may introduce some bias into
the results. Future studies with larger samples sizes are
required to refine these thresholds and determine the
impact of varying degrees of disease severity on these es-
timations of the MID for the 6MWD and the ISWD. In addi-
tion, the MID values were derived from the GROC following
an eight-week exercise intervention program [26]. Whether
these estimates apply to other types of interventions,
including medical therapy and airway clearance tech-
niques, is unknown.
In conclusion, this study provides the first estimates of
the MID for the 6MWD and ISWD in individuals with well-
defined non-CF bronchiectasis, with thresholds of 25 m and
35 m respectively. These results lend support to the
application of these field walking tests as outcome mea-
sures in bronchiectasis, thus potentially facilitating the
interpretation of future research findings and providing
clinicians with quantifiable goals related to exercise out-
comes following treatment.Acknowledgements
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